FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096104293> ?p ?o ?g. }

• W2096104293 endingPage "85" @default.
• W2096104293 startingPage "2778" @default.
• W2096104293 abstract "Previous studies directed at identifying paclitaxel resistance genes in a paclitaxel-resistant subclone of the human ovarian cancer cell line SKOV-3 identified a novel cancer testis antigen, Taxol resistance-associated gene 3 (TRAG-3). Because investigation suggested that TRAG-3, located on chromosome Xq28, does not directly participate in the paclitaxel-resistant phenotype, it was hypothesized that TRAG-3 might be linked to a neighboring gene that is directly involved in the drug-resistant phenotype, or alternatively, overexpression of TRAG-3 might be attributable to coregulation with other cancer testis antigens. To distinguish between these two hypotheses, expression of the genes that flank TRAG-3 was evaluated, namely the Centrin 2 gene and several members of the MAGE gene cluster. Northern analysis demonstrates overexpression of MAGE2 but not Centrin 2. Extension of this analysis to other neighboring and non-neighboring representative cancer testis antigens reveals overexpression of MAGE3, MAGE6, MAGE11, and MAGE12, as well as GAGE-2, GAGE-4, GAGE-5, GAGE-6, and GAGE-7 (clustered on Xp11) in SKOV-3(TR), as compared with SKOV-3. In addition, Affymetrix-based analysis of gene expression in SKOV-3 subclones with variable paclitaxel resistance demonstrates MAGE gene overexpression occurs early in the development of the paclitaxel-resistant phenotype, whereas GAGE gene overexpression occurs somewhat later. Evaluation of additional breast and ovarian cancer cell lines reveals MAGE/GAGE overexpression in both paclitaxel- and doxorubicin-resistant cell lines, whereas gemcitabine-resistant subclones of several ovarian cancer cell lines, including SKOV-3(GR), reveals no change in MAGE/GAGE expression. To determine whether MAGE gene overexpression contributes directly to the drug-resistant phenotype, MAGE2 or MAGE6, cDNA was introduced into the paclitaxel-sensitive human ovarian cancer cell line OVCAR8. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity analysis of both MAGE2 and MAGE6 transfectants demonstrates a 4-fold increase in resistance to paclitaxel and 2-fold increase in resistance to doxorubicin but not to other drugs, such as topotecan and cisplatin, through a nonmultidrug resistance-1 mechanism. MAGE2 or MAGE6 overexpression also induces a growth advantage in OVCAR8-transfected cells. These studies suggest that the in vitro acquisition of paclitaxel and doxorubicin resistance can be associated with increased expression of a variety of both neighboring and non-neighboring cancer testis antigens genes. This does not appear to be a consequence of random genetic instability or genomic amplification of the X chromosome. These antigens, because of limited expression in normal tissues, may be suitable targets for immunotherapy and novel therapeutic strategies in the treatment of chemotherapy-resistant epithelial tumors." @default.
• W2096104293 created "2016-06-24" @default.
• W2096104293 creator A5000311133 @default.
• W2096104293 creator A5023603789 @default.
• W2096104293 creator A5025835931 @default.
• W2096104293 creator A5055817420 @default.
• W2096104293 creator A5079752398 @default.
• W2096104293 creator A5087212097 @default.
• W2096104293 creator A5089955620 @default.
• W2096104293 date "2003-07-01" @default.
• W2096104293 modified "2023-09-25" @default.
• W2096104293 title "Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines." @default.
• W2096104293 cites W1513362785 @default.
• W2096104293 cites W1555492741 @default.
• W2096104293 cites W1595529034 @default.
• W2096104293 cites W1709424591 @default.
• W2096104293 cites W1781302273 @default.
• W2096104293 cites W1826726872 @default.
• W2096104293 cites W1924717348 @default.
• W2096104293 cites W1953419682 @default.
• W2096104293 cites W1970020334 @default.
• W2096104293 cites W1978166647 @default.
• W2096104293 cites W1980293803 @default.
• W2096104293 cites W1981801694 @default.
• W2096104293 cites W1990821176 @default.
• W2096104293 cites W1997174909 @default.
• W2096104293 cites W2006987944 @default.
• W2096104293 cites W2007988465 @default.
• W2096104293 cites W2015303818 @default.
• W2096104293 cites W2018015329 @default.
• W2096104293 cites W2033442994 @default.
• W2096104293 cites W2036708294 @default.
• W2096104293 cites W2040353607 @default.
• W2096104293 cites W2049110191 @default.
• W2096104293 cites W2058180125 @default.
• W2096104293 cites W2062668639 @default.
• W2096104293 cites W2062713892 @default.
• W2096104293 cites W2070481770 @default.
• W2096104293 cites W2073252143 @default.
• W2096104293 cites W2074144048 @default.
• W2096104293 cites W2076031566 @default.
• W2096104293 cites W2090575285 @default.
• W2096104293 cites W2095575390 @default.
• W2096104293 cites W2098988128 @default.
• W2096104293 cites W2109047753 @default.
• W2096104293 cites W2110271221 @default.
• W2096104293 cites W2125089526 @default.
• W2096104293 cites W2140383812 @default.
• W2096104293 cites W2140927361 @default.
• W2096104293 cites W2141543852 @default.
• W2096104293 cites W2147293836 @default.
• W2096104293 cites W2152630182 @default.
• W2096104293 cites W2163636540 @default.
• W2096104293 cites W2184627161 @default.
• W2096104293 cites W2272017712 @default.
• W2096104293 cites W2328421677 @default.
• W2096104293 cites W2414494253 @default.
• W2096104293 cites W2412192011 @default.
• W2096104293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12855658" @default.
• W2096104293 hasPublicationYear "2003" @default.
• W2096104293 type Work @default.
• W2096104293 sameAs 2096104293 @default.
• W2096104293 citedByCount "37" @default.
• W2096104293 countsByYear W20961042932012 @default.
• W2096104293 countsByYear W20961042932014 @default.
• W2096104293 countsByYear W20961042932015 @default.
• W2096104293 countsByYear W20961042932016 @default.
• W2096104293 countsByYear W20961042932017 @default.
• W2096104293 countsByYear W20961042932018 @default.
• W2096104293 countsByYear W20961042932019 @default.
• W2096104293 countsByYear W20961042932022 @default.
• W2096104293 crossrefType "journal-article" @default.
• W2096104293 hasAuthorship W2096104293A5000311133 @default.
• W2096104293 hasAuthorship W2096104293A5023603789 @default.
• W2096104293 hasAuthorship W2096104293A5025835931 @default.
• W2096104293 hasAuthorship W2096104293A5055817420 @default.
• W2096104293 hasAuthorship W2096104293A5079752398 @default.
• W2096104293 hasAuthorship W2096104293A5087212097 @default.
• W2096104293 hasAuthorship W2096104293A5089955620 @default.
• W2096104293 hasConcept C104317684 @default.
• W2096104293 hasConcept C121608353 @default.
• W2096104293 hasConcept C2776694085 @default.
• W2096104293 hasConcept C2777292972 @default.
• W2096104293 hasConcept C2780427987 @default.
• W2096104293 hasConcept C2781303535 @default.
• W2096104293 hasConcept C502942594 @default.
• W2096104293 hasConcept C54355233 @default.
• W2096104293 hasConcept C86803240 @default.
• W2096104293 hasConceptScore W2096104293C104317684 @default.
• W2096104293 hasConceptScore W2096104293C121608353 @default.
• W2096104293 hasConceptScore W2096104293C2776694085 @default.
• W2096104293 hasConceptScore W2096104293C2777292972 @default.
• W2096104293 hasConceptScore W2096104293C2780427987 @default.
• W2096104293 hasConceptScore W2096104293C2781303535 @default.
• W2096104293 hasConceptScore W2096104293C502942594 @default.
• W2096104293 hasConceptScore W2096104293C54355233 @default.
• W2096104293 hasConceptScore W2096104293C86803240 @default.
• W2096104293 hasIssue "7" @default.

• next